Update on timing of preliminary results

Avacta

27/05/2025 07:00

RNS Number : 1215K

Avacta Group PLC

27 May 2025

 

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Update on timing of preliminary results announcement

 

LONDON and PHILADELPHIA - May 27, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces that the preliminary results for year ended December 31, 2024 will now be published on June 4, 2025 as the Group's auditors have been unable to finalise the audit work connected to the disposal of Launch Diagnostics, which completed post period end, by the originally planned date of May, 29 2025. The Group was notified of this development on May 23, 2025. 

 

There is no impact to Avacta's financial position and cash runway.

 

Christina Coughlin, Chief Executive Officer and Brian Hahn, Chief Financial Officer will now deliver the planned live presentation via Investor Meet Company at 11:00 BST on June 4, 2025.

The presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and add to meet AVACTA GROUP PLC via:

https://www.investormeetcompany.com/avacta-group-plc/register-investor. 

 

Investors who already follow Avacta on the Investor Meet Company platform will automatically be invited.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard up until June 4 at 09:00 BST, or at any time during the live presentation.

 

The Company will also post the results presentation on its website at the following page: https://avacta.com/investors/investor-resources/.

 

 

 

-Ends -

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc
Michael Vinegrad, Group Communications
Director
https://avacta.com/
Peel Hunt (Nomad and Joint Broker)
James Steel / Chris Golden
www.peelhunt.com
Panmure Liberum (Joint Broker)
Emma Earl / Will Goode / Mark Rogers
ICR Healthcare
Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert
www.panmureliberum.com
avacta@icrhealthcare.com
Investor Contact
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
Media Contact
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com

 

 

About Avacta - www.avacta.com

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

 

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.

  

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NORDGGDUUXDDGUL